Studies of alirocumab in people
6 studies gave alirocumab to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases CERT2Approximately 2 risk-score points lower than placebo | Treated cohort4 months | 4,285 peoplePatient cohorts | AHA Scientific Sessions 2026 abstract, Nov 2, 2026 |
| Randomized trial52 weeks | 125 peopleBoth59 (51; 64) yearsPatients with acute coronary syndrome not achieving LDL-cholesterol target with statin therapy | Journal of clinical medicine, Sep 29, 2026 | |
up: Increases carotid plaque regressionregression proportions exceeded 30% down: Decreases intraplaque neovascularization down: Decreases LDL-C | Randomized trial12 months | 299 peoplePatients with high CVD risk with non-calcified plaque on the carotid artery | Frontiers in pharmacology, Aug 27, 2026 |
down: Decreases LDL cholesterol-34.1% | Trial1 month | 26 peopleAfter acute coronary syndrome, switched from inclisiran | Terapevticheskii arkhiv, Mar 7, 2026 |
down: Decreases ceramide | Randomized trial | 265 peopleIn patients with acute myocardial infarction | Circulation. Genomic and precision medicine, Feb 10, 2026 |
down: Decreases major adverse cardiovascular eventsHR 0.78 (0.68-0.91) for ≥65 years down: Decreases all-cause deathHR 0.77 (0.62-0.95) for ≥65 years no change: Has no effect on adverse events | Randomized trial | 18,924 people≥65 yearsOlder adults; patients aged ≥65 years; consistent with <65 years | European heart journal, Nov 17, 2019 |